Clinical trials: Ovarian Diseases
Ovarian Cancer, Peritoneal Cavity Cancer
Docetaxel and Carboplatin in Treating Patients With Relapsed Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cavity Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00217568
- Testing
- pegfilgrastim, carboplatin, docetaxel
- Where
- 3 sites in United States
- Sponsor
- Fred Hutchinson Cancer Center
Ovarian Cancer, Serous Ovarian Cancer
Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer
To see how effective the study medicine combined with hormone therapy is when given to participants with recurrent low-grade serous ovarian cancer.
- Trial name
- NCT05113368
- Testing
- Regorafenib, Fulvestrant
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Sarah K. Lynam MD
Ovarian Carcinoma
PEP-DC and OC-DC Vaccine in High Grade Serous Ovarian Carcinoma
Single center, phase I/II randomized 2-arm study, evaluating two different vaccination regimens combined with low-dose cyclophosphamide in patients with advanced high grade serous ovarian carcinoma (HGSOC): Arm A patients will be…
- Trial name
- CHUV-OVACURE (NCT05714306)
- Testing
- PEP-DC1, OC-DC, PEP-DC2
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Ovarian Cancer, Ovarian Neoplasms
Spectroscopy in Ovarian Cancer
Ovarian cancer is the eighth most common cause of cancer death in the world. Advanced stage at diagnosis is associated with lower survival rates, thus early detection appears to have an important role.
- Conditions
- Ovarian Cancer, Ovarian Neoplasms, Ovary Cyst, Ovary Disease
- Trial name
- NCT04817449
- Where
- United Kingdom
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- University of Exeter
Ovarian Cancer
NeoVax With Nivolumab in Patients With Ovarian Cancer
This research study is evaluating a new type of vaccine called "Personalized NeoAntigen Cancer Vaccine" in combination with Nivolumab (Opdivo®) for ovarian cancer.
- Trial name
- NCT04024878
- Testing
- Nivolumab, NeoVax, Core Needle Biopsy
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Dana-Farber Cancer Institute
Gynecologic Malignant Tumor
The Study of Massively Parallel Sequencing in Early Detection for Gynecologic Malignant Tumor
As human aging, 50% of women will be faced with the threat of cancer, especially gynecological malignancies. Ovarian, cervical and endometrial cancer are three major gynecological malignancies.
- Trial name
- NCT02166515
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Zhiqing, Liang
Anal Carcinoma, Bladder Carcinoma
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
This phase I trial is evaluating a new imaging tracer (68Ga-FAPi-46) with positron emission tomography (PET)/computed tomography (CT) to determine where and to which degree the tracer (68Ga-FAPi-46) accumulates in normal and…
- Conditions
- Anal Carcinoma, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma
- Trial name
- NCT07118176
- Testing
- Computed Tomography, Fludeoxyglucose F-18, Gallium Ga 68 FAPi-46
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Advanced Malignant Solid Neoplasm, Fibrolamellar Carcinoma
Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
This phase I trial studies the side effects and best dose of sapanisertib and ziv-aflibercept in treating patients with solid tumors that have come back (recurrent) and have spread to another place in the body (metastatic) or…
- Conditions
- Advanced Malignant Solid Neoplasm, Fibrolamellar Carcinoma, Metastatic Malignant Solid Neoplasm, Ovarian Carcinoma
- Trial name
- NCT02159989
- Testing
- Sapanisertib, Ziv-Aflibercept
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer
Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian Cancer
RATIONALE: Drugs used in chemotherapy, such as doxorubicin and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00562185
- Testing
- carboplatin, doxorubicin hydrochloride
- Where
- United States
- Sponsor
- University of Texas Southwestern Medical Center
Epithelial Ovarian Cancer
A Study to Explore Pamiparib Treatment in Epithelial Ovarian Cancer After Prior PARP Inhibitor Exposure
The PamiAP will be a Phase II, single-arm, open label study to explore the efficacy and safety of Pamiparib treatment in patients with Epithelial Ovarian Cancer（EOC） who have had exposure to prior a PARP…
- Trial name
- NCT05489926
- Testing
- Pamiparib
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Zhejiang Cancer Hospital
Malignant Neoplasms
A Study of DEG6498 in Participants With Solid Tumors
The goal of this first in human, Phase 1, multi-center, open-label, and 2-part study is to learn whether DEG6498 is safe and tolerable in participants with advanced solid tumors.
- Trial name
- NCT07244835
- Testing
- DEG6498
- Where
- 3 sites in China
- Volunteers
- 100 people
- Sponsor
- Degron Therapeutics Co.
Stage IV Ovarian Cancer, Testis Cancer, Refractory
CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors
This study is an open, exploratory clinical study to evaluate the safety and preliminary efficacy of Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells in patients with Claudin6, GPC3, Mesothelin, or AXL-positive advanced…
- Conditions
- Stage IV Ovarian Cancer, Testis Cancer, Refractory, Endometrial Cancer Recurrent, CAR NK
- Trial name
- NCT05410717
- Testing
- Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Polycystic Ovary Syndrome
A Reduced Carbohydrate Diet Intervention for Polycystic Ovary Syndrome (PCOS)
Polycystic ovary syndrome (PCOS) affects 5-10% of women of reproductive age, and is associated with infertility, risk for obesity and type 2 diabetes, and impaired quality of life.
- Trial name
- NCT01028989
- Testing
- Reduced Glycemic Load Diet, Standard Diet
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of ixabepilone in treating young…
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer
- Trial name
- NCT00030108
- Testing
- ixabepilone
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Ovarian Neoplasm, Chemotherapeutic Toxicity
Trabectedin/Caelyx vs Cisplatin Hypersensitivity in Relapsed Ovarian Cancer Patients Allergic to Platinum
Observational, clinical study. Intention to include 40 patients (20 patients treated with trabectedin and 20 with cisplatin hypersensitivity) The investigators investigate the role of trabectedin in combination with PLD and…
- Conditions
- Ovarian Neoplasm, Chemotherapeutic Toxicity, Chemotherapy Effect, Chemotherapy-induced Neutropenia
- Trial name
- TvsCH (NCT05512676)
- Volunteers
- 40 people
- Sponsor
- Oslo University Hospital
Mesothelioma, Mesothelioma, Malignant
Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
Gavocabtagene autoleucel (gavo-cel; TC-210) is a novel cell therapy that consists of autologous genetically engineered T cells expressing a single-domain antibody that recognizes human Mesothelin, fused to the CD3-epsilon subunit…
- Conditions
- Mesothelioma, Mesothelioma, Malignant, Mesothelioma; Pleura, Mesotheliomas Pleural
- Trial name
- NCT03907852
- Testing
- gavo-cel, fludarabine, cyclophosphamide
- Where
- 11 sites in United States, Canada
- Volunteers
- 57 people
- Sponsor
- TCR2 Therapeutics
Ovarian Neoplasm Epithelial, Ovarian Cancer
Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer
A clinical study to compare the efficacy and safety of five administrations of oregovomab versus placebo, infused in schedule dependent sequence with specific cycles of a standard six-cycle chemotherapy regimen (paclitaxel and…
- Conditions
- Ovarian Neoplasm Epithelial, Ovarian Cancer, Fallopian Tube Neoplasms, Peritoneal Carcinoma
- Trial name
- NCT05605535
- Testing
- Oregovomab, Paclitaxel, Carboplatin
- Where
- 14 sites in India
- Volunteers
- 88 people
- Sponsor
- CanariaBio Inc.
Ovarian Cancer, Sarcoma
Chemotherapy in Treating Patients With Advanced Sarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00002526
- Testing
- filgrastim, doxorubicin hydrochloride, ifosfamide
- Where
- Switzerland
- Volunteers
- 20 people
- Sponsor
- Swiss Cancer Institute
Polycystic Ovary Syndrome, Insulin Resistance
The Role of Insulin Resistance in PCOS
Polycystic ovary syndrome (PCOS) phenotype can be structured into three components: anovulation, hyperandrogenism and the metabolic syndrome (of which hyperinsulinemia, secondary to insulin resistance, is the central…
- Conditions
- Polycystic Ovary Syndrome, Insulin Resistance, Obesity
- Trial name
- NCT00173043
- Where
- Taiwan
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Infertility, Female
150 IU vs. 225 IU FSH in Normal Responders: The OPTIMAL-DOSE Trial
This is a single-center, randomized, open-label, non-inferiority trial comparing two fixed daily doses of follicle-stimulating hormone (FSH): 150 IU versus 225 IU in women with predicted normal ovarian response undergoing in…
- Trial name
- OPTIMAL-DOSE (NCT07346235)
- Testing
- Follicle-stimulating hormone (FSH)
- Sponsor
- American Hospital 2 Kosovo
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.